Exicure Inc (XCUR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.25+1.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XCUR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 40.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
XCUR — director transition
Dated 2026-06-30
Director — Ham Jung Kyu: The resignation of Ham Jung Kyu did not result from any disagreement with the company.
Why it matters: Watching cash burn is key to knowing if Exicure can stay financially healthy.
Worry ifOperating costs drop a lot compared to past quarters.
Less concerning ifOperating costs go up or stay high, showing ongoing cash burn.
Why it matters: The results will show if Exicure is making progress in managing expenses and cash burn.
Watch forQ2 2026 results show smaller operating losses than Q1 2026.
Also watch forQ2 2026 results show ongoing or larger operating losses.
Why it matters: Changes in leadership can affect the company's plans and how well it runs.
Watch forNew executive hires are announced. They make the leadership team stronger.
Also watch forMore resignations or problems in the executive team.
Why it matters: Approval would end ongoing lawsuits. It may also improve how Exicure is run.
Supportive ifThe court approves the proposed settlement on June 2, 2026.
Worry ifThe court rejects the settlement. This means lawsuits will continue.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$364 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $1,080 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,422 loss on $10,000 · 84.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Advancing clinical programs is key for Exicure's future. It also helps stockholder value.
Supportive ifManagement says a big milestone will be reached in the main clinical program by Q4 2026.
Worry ifNo progress reported on clinical milestones by the end of Q4 2026.
Why it matters: Regaining compliance is key to keeping the company's listing. It also helps investor confidence. Not being compliant could lead to delisting.
Worry ifThe company confirms it has met Nasdaq listing rules again.
Less concerning ifThe company gets another notice for not being compliant from Nasdaq.
Why it matters: Filing on time is important for compliance. It also helps maintain investor trust after delays.
Worry ifThe company files its next quarterly report by the end of Q3 2026.
Less concerning ifThe company fails to file the next quarterly report by the deadline.
Why it matters: Advancing clinical milestones is key for growth. It shows the company is moving forward.
Supportive ifThey said they finished an important step in a clinical trial.
Worry ifNo updates or delays on clinical trials for the next quarter.
Why it matters: The court's decision on the settlement affects Exicure's legal risks. A good outcome can help the company.
Supportive ifThe court approves the settlement and ends the derivative lawsuit.
Worry ifThe court rejects the settlement. This leads to more litigation and uncertainty.